Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$152.58
+0.1%
$153.66
$140.68
$169.99
$366.71B0.428.02 million shs9.00 million shs
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
$6.47
$6.47
$5.73
$8.75
$644.67M0.01N/AN/A
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.09%+0.83%-1.55%-0.43%+4.39%
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.9564 of 5 stars
3.35.04.23.93.01.71.9
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.55
Moderate Buy$170.8812.00% Upside
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest JNJ and SVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/5/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$181.00
5/13/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/13/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$169.00 ➝ $153.00
4/24/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/17/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$166.00 ➝ $165.00
4/16/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
4/16/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.00
4/16/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$164.00 ➝ $169.00
4/14/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$165.00 ➝ $162.00
4/10/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$171.00 ➝ $159.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$88.82B4.13$13.13 per share11.62$29.69 per share5.14
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
$448.27M1.44$0.17 per share38.95$120.83 per share0.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$14.07B$8.9916.9713.782.3124.42%33.46%13.30%7/16/2025 (Estimated)
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
-$99.92MN/A0.00N/AN/AN/AN/AN/A

Latest JNJ and SVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/16/2025Q2 2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.65N/AN/AN/A$22.85 billionN/A
4/15/2025Q1 2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.59$2.77+$0.18$4.54$21.65 billion$21.89 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.203.41%N/A57.84%64 Years
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
N/AN/AN/AN/AN/A

Latest JNJ and SVA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
--$55.007/8/20255/23/20257/7/2025
4/15/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.303.37%5/27/20255/27/20256/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.49
1.26
1.03
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
N/A

Insider Ownership

CompanyInsider Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
12.79%
CompanyEmployeesShares OutstandingFree FloatOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,1002.41 billion2.40 billionOptionable
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
3,26199.64 million86.89 millionOptionable

Recent News About These Companies

SINOVAC Announces New Board Member

New MarketBeat Followers Over Time

Media Sentiment Over Time

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$152.58 +0.17 (+0.11%)
As of 06/30/2025 03:58 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Sinovac Biotech stock logo

Sinovac Biotech NASDAQ:SVA

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.